CLAIMS

1. Use of dextromethorphan in the manufacture of a medicament for treating depression in a human being, wherein the medicament is to be co-administered with bupropion, and wherein the human being is an extensive metabolizer of dextromethorphan.

2. Use of claim 1, wherein bupropion is to be co-administered with dextromethorphan for at least eight consecutive days.

3. Use of claim 2, wherein, on the eighth day, dextromethorphan has a plasma level 12 hours after co-administration of bupropion with dextromethorphan that is at least 80 times the plasma level that would be achieved by administration of the same amount of dextromethorphan without co-administration of bupropion.

4. Use of any one of claims 1 to 3, wherein about 40 mg to about 140 mg of dextromethorphan is to be administered per day.

5. Use of claim 4, wherein about 60 mg to about 100 mg of dextromethorphan is to be administered per day.

6. Use of any one of claims 1 to 3, wherein about 100 mg to about 250 mg of bupropion is to be administered per day.

7. Use of any one of claims 1 to 3, wherein about 200 mg to about 250 mg of bupropion is to be administered per day.

8. Use of any one of claims 1 to 7, wherein bupropion is to be administered in an amount that results in a plasma concentration of dextromethorphan in the human being on the eighth day that is at least 10 times the plasma concentration of the same amount of dextromethorphan administered without bupropion.

9. Use of any one of claims 1 to 8, wherein bupropion is to be co-administered with dextromethorphan for the treatment of agitation.

10. Use of any one of claims 1 to 9, wherein the bupropion is to be co-administered with dextromethorphan in a single dosage form.